JP6712993B2 - 免疫細胞を惹起及び／又は活性化するための免疫応答刺激性サイトカインを発現する遺伝子改変型間葉系幹細胞 - Google Patents

免疫細胞を惹起及び／又は活性化するための免疫応答刺激性サイトカインを発現する遺伝子改変型間葉系幹細胞 Download PDF

Info

Publication number
JP6712993B2
JP6712993B2 JP2017509626A JP2017509626A JP6712993B2 JP 6712993 B2 JP6712993 B2 JP 6712993B2 JP 2017509626 A JP2017509626 A JP 2017509626A JP 2017509626 A JP2017509626 A JP 2017509626A JP 6712993 B2 JP6712993 B2 JP 6712993B2
Authority
JP
Japan
Prior art keywords
cells
tumor
cell
immune
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017509626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525364A (ja
JP2017525364A5 (enExample
Inventor
ギュンター，クリスチーネ
テオハリス，ステファノ
ヘルマン，フェリクス
フス，ラルフ
Original Assignee
アプセト ゲーエムベーハー アンド ツェーオー．カーゲー
アプセト ゲーエムベーハー アンド ツェーオー．カーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプセト ゲーエムベーハー アンド ツェーオー．カーゲー, アプセト ゲーエムベーハー アンド ツェーオー．カーゲー filed Critical アプセト ゲーエムベーハー アンド ツェーオー．カーゲー
Publication of JP2017525364A publication Critical patent/JP2017525364A/ja
Publication of JP2017525364A5 publication Critical patent/JP2017525364A5/ja
Application granted granted Critical
Publication of JP6712993B2 publication Critical patent/JP6712993B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017509626A 2014-08-18 2015-08-18 免疫細胞を惹起及び／又は活性化するための免疫応答刺激性サイトカインを発現する遺伝子改変型間葉系幹細胞 Active JP6712993B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14181283.4 2014-08-18
EP14181283 2014-08-18
PCT/EP2015/068942 WO2016026854A2 (en) 2014-08-18 2015-08-18 Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells

Publications (3)

Publication Number Publication Date
JP2017525364A JP2017525364A (ja) 2017-09-07
JP2017525364A5 JP2017525364A5 (enExample) 2018-09-20
JP6712993B2 true JP6712993B2 (ja) 2020-06-24

Family

ID=51352460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017509626A Active JP6712993B2 (ja) 2014-08-18 2015-08-18 免疫細胞を惹起及び／又は活性化するための免疫応答刺激性サイトカインを発現する遺伝子改変型間葉系幹細胞

Country Status (8)

Country Link
US (2) US20170239297A1 (enExample)
EP (2) EP3182984B1 (enExample)
JP (1) JP6712993B2 (enExample)
CN (1) CN106659742B (enExample)
AU (1) AU2015306231B2 (enExample)
CA (1) CA2956987C (enExample)
IL (1) IL250388B (enExample)
WO (1) WO2016026854A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
WO2015124297A1 (en) * 2014-02-19 2015-08-27 Merck Patent Gmbh Cancer-targeted il-12 immunotherapy
JP6971986B2 (ja) * 2016-04-01 2021-11-24 アプセト ゲーエムベーハー アンド ツェーオー．カーゲー 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞
WO2018071295A1 (en) * 2016-10-10 2018-04-19 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for inducible production of anti-inflammatory cytokines
CN108148862B (zh) 2016-12-05 2019-03-08 上海优卡迪生物医药科技有限公司 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用
JP2020509773A (ja) * 2017-03-17 2020-04-02 センティ バイオサイエンシズ インコーポレイテッド 免疫調節性細胞回路
KR20190133254A (ko) * 2017-04-07 2019-12-02 시나타 세라퓨틱스 엘티디 키메라 항원 수용체 (car) t 세포 요법의 부작용을 치료하는 방법
KR20190141695A (ko) * 2017-04-13 2019-12-24 센티 바이오사이언시스, 인코포레이티드 병용 암 면역요법
CN107184603B (zh) * 2017-06-01 2020-06-30 刘未斌 一种治疗肿瘤的药物组合
CN107184602B (zh) * 2017-06-01 2020-06-30 刘未斌 一种治疗肿瘤的药物组合
CA3066799A1 (en) * 2017-06-16 2018-12-20 Cynata Therapeutics Limited Method for treating a side effect of immunotherapy
WO2019067491A1 (en) * 2017-09-29 2019-04-04 Oncocyclist, Inc. COMPOSITION AND METHOD FOR TREATING CELL PROLIFERATION
US12016882B2 (en) 2017-11-22 2024-06-25 The Brigham And Women's Hospital, Inc. Method of treating glioblastoma multiforme
TR201900059A2 (tr) 2018-01-05 2019-07-22 Gnt Biotech & Medicals Corp Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem
AU2019206643A1 (en) * 2018-01-12 2020-07-23 Rutgers, The State University Of New Jersey Cell reprogramming therapy
JP7102670B2 (ja) * 2018-01-25 2022-07-20 アイ－エムエービー バイオファーマ ユーエス リミテッド 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合
JP2021512950A (ja) * 2018-02-02 2021-05-20 エスエル・ベクシジェン・インコーポレイテッドＳｌ Ｖａｘｉｇｅｎ， Ｉｎｃ． 新規なワクチンの免疫補助剤
CN111836888B (zh) * 2018-03-21 2024-01-12 洪明奇 用于癌症治疗的工程化干细胞
CN108864288A (zh) * 2018-04-26 2018-11-23 上海怡豪生物科技有限公司 乳腺癌的双靶点car-t治疗载体及其构建方法和应用
CN110527696A (zh) * 2018-06-13 2019-12-03 中山大学 一种IFNβ和FerritinH基因联合修饰的骨髓间充质干细胞及其制备方法和应用
CN108815188A (zh) * 2018-07-06 2018-11-16 浙江生创精准医疗科技有限公司 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途
CN112384231A (zh) * 2018-08-26 2021-02-19 奥伊斯细胞生物技术公司 用于治疗胶质母细胞瘤的方法
CN112771167B (zh) * 2018-09-20 2025-09-26 克莱格医学有限公司 表达有趋化因子的细胞及用途
US20210338729A1 (en) * 2018-10-12 2021-11-04 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF
CA3116138A1 (en) * 2018-10-17 2020-04-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN109593725A (zh) * 2018-12-25 2019-04-09 河北生命原点生物科技有限公司 一种重组间充质干细胞及其应用
MX2021009785A (es) * 2019-02-14 2021-09-08 Res Institute At Nationwide Children´S Hospital Uso de particulas de membrana plasmatica, liposomas y exosomas para evaluar la potencia de celulas inmunitarias.
CN109762820B (zh) * 2019-02-18 2020-07-28 河北佑仁生物科技有限公司 一种骨髓间充质干细胞特异性启动元件在干细胞中的应用
US20220143099A1 (en) * 2019-04-02 2022-05-12 The General Hospital Corporation Methods to enhance t cell regeneration
CN115851605A (zh) * 2019-04-18 2023-03-28 上海交通大学 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法
CN111139222B (zh) * 2019-05-30 2020-12-29 北京双因生物科技有限公司 一种重组间充质干细胞及其制备方法和用途
EP4556072A3 (en) * 2019-08-23 2025-06-11 Orbsen Therapeutics Limited Compositions for monocyte and macrophage polarization and methods of use
US20230105923A1 (en) * 2020-03-26 2023-04-06 Agency For Science, Technology And Research A method and system for introducing one or more exogenous substances into an immune cell
JP7820823B2 (ja) * 2020-05-27 2026-02-26 ウニヴェルジテート・チューリッヒ 骨髄性細胞およびミクログリアにおいて特異的に治療タンパク質を発現するウイルスベクター
JP7758370B2 (ja) * 2020-07-16 2025-10-22 チャンジェン セラピューティクス （シャンハイ） カンパニー リミテッド 間葉系幹細胞によるケモカインおよびサイトカイン送達を標的とする免疫療法
WO2022079322A1 (en) * 2020-10-16 2022-04-21 Fundació Centre De Regulació Genòmica Therapy for degenerative disease and tissue damage
CN114507643A (zh) * 2020-10-29 2022-05-17 未来智人再生医学研究院(广州)有限公司 一种表达il-2的多能干细胞衍生物及应用
CN114426953A (zh) * 2020-10-29 2022-05-03 未来智人再生医学研究院(广州)有限公司 一种表达il-12的多能干细胞衍生物及应用
CN114717232A (zh) * 2020-12-22 2022-07-08 未来智人再生医学研究院(广州)有限公司 表达irf-1靶向抑制因子的多能干细胞及其衍生物与应用
WO2023274355A1 (zh) * 2021-07-02 2023-01-05 上海交通大学 改造的间充质干细胞和免疫效应细胞联合治疗肿瘤
WO2023076670A1 (en) * 2021-11-01 2023-05-04 MAM Holdings of West Florida, L.L.C. Mesenchymal stem cells for the prevention and targeted treatment of cancer and other disorders
CN114480413B (zh) * 2022-01-14 2022-11-04 北京贝来生物科技有限公司 一种活化肿瘤免疫应答的基因修饰干细胞制备方法
CN115463155B (zh) * 2022-11-01 2023-05-23 卡瑞济(北京)生命科技有限公司 间充质干细胞的用途
CN117503952B (zh) * 2022-11-24 2025-09-16 中国药科大学 一种基于血小板的免疫激活系统及其制备方法和应用
WO2024137869A2 (en) * 2022-12-20 2024-06-27 City Of Hope Stem cells for delivery of oncolytic viruses
US12655391B2 (en) * 2024-02-28 2026-06-16 Gene Solutions Joint Stock Company Modified K562 feeder cell line expressing factors that enhance the activation and proliferation of natural killer cells and a method for its production
WO2026069312A1 (en) 2024-09-24 2026-04-02 Yeda Research And Development Co. Ltd. Immune cells expressing an inducible therapeutic agent and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076622A1 (en) 2002-03-02 2004-04-22 Board Of Regents, The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
KR101130220B1 (ko) * 2003-06-27 2012-04-13 엔씨 메디컬 리서치 가부시키가이샤 간엽계 세포를 유효 성분으로 하는 뇌신경 질환 치료용 체내 투여용 약제
WO2005001732A1 (ja) * 2003-06-27 2005-01-06 Renomedix Institute Inc. 治療用自己細胞配送支援システム及び治療用自己細胞配送支援金融システム、並びにそれらの方法
US20050002904A1 (en) 2003-07-03 2005-01-06 Wary Kishore K. Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
RU2007113444A (ru) * 2004-09-10 2008-10-27 Когнейт Терапьютикс Стромальные клетки печени для профилактики и лечения иммунных реакций при трансплантации
EP1757703A3 (en) 2005-08-24 2007-12-05 Medizinische Hochschule Hannover Self-inactivating retroviral vector
ES2507507T3 (es) * 2007-05-24 2014-10-15 Apceth Gmbh & Co. Kg Células madre mesenquimales CD34 negativas modificadas genéticamente para el tratamiento de tumores
EP2019134A1 (en) 2007-07-26 2009-01-28 Vision 7 GmbH Gene therapy of chronic granulomatous disease
JP5727458B2 (ja) * 2009-04-13 2015-06-03 アプセト ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフトＡｐｃｅｔｈ Ｇｍｂｈ ＆ Ｃｏ． Ｋｇ 改変間葉系幹細胞及びそれを使用した腫瘍の治療方法
DK2510084T3 (da) * 2009-12-08 2020-04-27 The Board Of Trustees Of The Univ Of Illionis Stamcelleimmunmoduleringsanvendelsesfremgangsmåder og apparat
CN101974485A (zh) * 2010-11-12 2011-02-16 苏州大学 具有最佳迁移能力的间充质干细胞的制备方法及其应用
US9101597B2 (en) 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods
AR097570A1 (es) * 2013-09-06 2016-03-23 Consejo Nac De Investig Científicas Y Técnicas (Conicet) Composiciones y métodos para incrementar la migración de células mesenquimales del estroma hacia tumores
EP3097117B1 (en) * 2014-01-21 2023-10-04 Novartis Ag Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells

Also Published As

Publication number Publication date
CA2956987C (en) 2023-03-21
US20170239297A1 (en) 2017-08-24
CN106659742B (zh) 2021-09-03
WO2016026854A2 (en) 2016-02-25
JP2017525364A (ja) 2017-09-07
AU2015306231A1 (en) 2017-02-23
IL250388A0 (en) 2017-03-30
EP3182984B1 (en) 2019-10-30
EP3656387A2 (en) 2020-05-27
EP3656387A3 (en) 2020-07-01
EP3182984A2 (en) 2017-06-28
CA2956987A1 (en) 2016-02-25
CN106659742A (zh) 2017-05-10
WO2016026854A3 (en) 2016-04-14
US20200268802A1 (en) 2020-08-27
US11464806B2 (en) 2022-10-11
IL250388B (en) 2021-02-28
AU2015306231B2 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
US11464806B2 (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
US20220378842A1 (en) Combinatorial cancer immunotherapy
JP6971986B2 (ja) 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞
US11419898B2 (en) Combinatorial cancer immunotherapy
EP3610000A1 (en) Combinatorial cancer immunotherapy
WO2016146819A1 (en) Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
JP7820823B2 (ja) 骨髄性細胞およびミクログリアにおいて特異的に治療タンパク質を発現するウイルスベクター
JP2019170176A (ja) ケモカインレセプターと細胞接着分子を発現するｃｄ３陰性細胞の集団、およびその利用
US20230312671A1 (en) Grp78 targeted adoptive cell therapy
WO2021085497A1 (ja) がんを治療するための医薬、組み合わせ医薬、医薬組成物、免疫応答性細胞、核酸送達媒体、及び製品
JP2024170618A (ja) Ｎｋ細胞の活性化及び増幅のために遺伝的に操作された細胞株、及びその用途
CN113383069B (zh) 使用转化的t细胞培养脐带血来源的自然杀伤细胞的方法
EP3068875A1 (en) Post-natal hematopoeitic endothelial cells and their isolation and use
JP7477120B2 (ja) Ｎｋ細胞の活性化及び増幅のために遺伝的に操作された細胞株、及びその用途
CN116254230A (zh) 用于制备和扩增通用型人源化抗cd19 car-nk细胞的方法及其用途
HK1233546A1 (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
HK1233546B (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
US12453763B2 (en) Human vaccine compositions and methods for treating leukemia
WO2025166096A1 (en) Method of induction of immune cells into a memory-like state
HK40057204A (zh) 组合癌症免疫疗法
AU2014348603A1 (en) Post-natal hematopoeitic endothelial cells and their isolation and use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200512

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200602

R150 Certificate of patent or registration of utility model

Ref document number: 6712993

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250